3 Food Recalls You Need To Know About This Week
It's not every week that we report on contaminated food and faulty appliances that have led to hospitalizations and property damage. Find out why microwaveable chicken fettuccine Alfredo meals, mini fridges, and chocolate-covered almonds are under fire this week.
On June 17, FreshRealm recalled its chicken fettuccine Alfredo products after an ongoing investigation revealed that this item is likely linked to an outbreak strain of listeria monocytogenes.
The USDA's Food Safety and Inspection Service (FSIS) began exploring this link on March 19, after routine sampling detected the food pathogen.
The CDC reports that there have been 17 confirmed cases of listeriosis, but that the number of sick people is likely higher. (People who recover without going to the doctor aren't tested for listeria.) Three people died after eating food contaminated with listeria.
The now-recalled ready-to-eat meals were sold nationwide at Kroger and Walmart locations under brand names Marketside and Home Chef.Products: Marketside Grilled Chicken Alfredo with Fettuccine and Home Chef Heat & Eat Chicken Fettuccine AlfredoDate of Recall: June 17, 2025
Best By Dates: 06/27/25, 06/26/25 and 06/19/25 or prior
Plant Code Numbers: P-50784, P-47770, and P-47718
Distribution: NationwideIf you still have the product in your fridge or freezer, toss it immediately or return it to your store for a refund.
On June 18, the United States Consumer Product Safety Commission (CPSC) announced that AstroAI, the maker of beloved mini fridges sold at Target, Walmart, and online at Amazon.com, is recalling about 249,100 mini fridges.
The recall follows at least 70 reports of the mini fridges smoking, burning, melting, or catching fire. In two cases, the fires caused more than $360,000 in property damage. The CPSC revealed that the product's electrical switch can short-circuit, which can lead to fires and burns.
The mini fridges sold for about $40 on Amazon and AstroAI.com between June 2019 and June 2022.Product: AstroAI 6-Can Mini Fridge
Date of Recall: June 18, 2025
Model Number: LY0204A
Serial Number: Nine-digit serial number starts with 'S/N' and one of the following numbers: 19, 20, 21, 2201, 2202, or 2203
Dates Sold: Between June 2019 and June 2022If you have a recalled mini fridge, stop using the appliance immediately and contact AstroAI for a free replacement. Take a picture of the recalled appliance, showing the model and serial number. Send this photo to AstroAI at recall@astroai.com or via astroai.com/product-recall.
If you have questions about the recall, contact AstroAI Monday through Friday from 9 a.m. to 5 p.m. PT at 877-278-7624.
On June 13, Meijer announced a recall of Frederik's Dark Chocolate Almonds across six states. The reason? Due to a packaging and processing mix-up, the packages may also contain dark chocolate-covered cashews, which aren't disclosed on the label.
Tree nuts are one of the most common food allergens in the country. Someone with an allergy to cashews could unknowingly eat one and have a serious or life-threatening reaction. As of June 20, Meijer says it hasn't received any reports of illness related to this mix-up.Product: Frederik's Dark Chocolate Almonds in 12-ounce packages
Date of Recall: June 13
Sell By Date: 05/07/2026 or 05/28/2026
UPC Code: 7-08820-68730-1
Distribution: Michigan, Indiana, Illinois, Ohio, Kentucky, and Wisconsin
Product: Frederik's Dark Chocolate Almonds in an 8-count multipack
Date of Recall: June 13
Sell By Date: 05/05/2026
UPC Code: 7-19283-11923-0
Distribution: Michigan, Indiana, Illinois, Ohio, Kentucky, and WisconsinYou can return these items to Meijer for a refund. If you have any other questions, contact Meijer at 800-543-3704 from 7 a.m. to 1 a.m. ET any day of the week.
Read the original article on SIMPLYRECIPES
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
ThinkCareBelieve: Week 22 of America's Rise to Greatness under President Trump's Leadership
Washington, DC, June 21, 2025 (GLOBE NEWSWIRE) -- Link to ThinkCareBelieve's Article: has published an article about Week 22 of America's rise to greatness. This week entailed outstanding leadership by a steady hand through choppy waters and ThinkCareBelieve's article shows how the President kept moving forward at a strong, surefooted pace. ThinkCareBelieve's article has important progress made at the G7 and the signing of major trade agreements as tensions between Iran and Israel took place. The message from Press Secretary Karoline Leavitt this week was "Trust in President Trump." Great nations are made because of great leaders and this week was proof of it. America has just had the highest wage increase in 60 years and the article has it. Real blue collar wages are up nearly 2%! America's low inflation and rising wages is a sure sign of success. Two new 88 foot high flag poles were installed this week, a magnificent addition to the White House grounds. The article has the latest on the status of student visas from Secretary of State Marco Rubio and President Trump's approval numbers keep going up! The article covers the Genius Act being passed by the Senate and the announcement that 70,000 people have signed up for President Trump's Gold Card Visa. The article has an abundance of reasons the One Big Beautiful Bill will benefit Americans. The OBBB will drive growth and supercharge the American economy. The article even has a tax-free tips and overtime calculator to see the average savings in your state: The article has statements by Dr. OZ the Administrator of the Center for Medicaid and Medicare Services on just how the One Big Beatiful Bill will help the most vulnerable of us who will suffer if the OBBB is not passed. The article also covers the great strides made by Secretary Kennedy convincing major food manufacturers to remove artificial food dyes and chemicals from their foods. The article also has an announcement by U.S. Attoney Jeanine Pirro of the U.S. Department of Justice crackdown on Crypto Currency Confidence Scams with confiscation and seizure of stolen money being returned back to the victims. Numerous investigations commenced this week and ThinkCareBelieve's article has the surge in attacks on ICE as they tried to do their jobs arresting criminal illegal aliens, catching child predators and dismantling trafficking networks. President Trump is the Man in the Arena and we are witessing history seeing how this man leads us through the muck and the mire to peace and prosperity in America's Golden Age. is an outlook. ThinkCareBelieve's mission for Peace advocacy facilitates positive outcomes and expanded possibilities. To achieve Peace, we will find the commonalities between diverse groups and bring the focus on common needs, working together toward shared goals. Activism is an important aspect of ThinkCareBelieve, because public participation and awareness to issues needing exposure to light leads to justice. Improved transparency in government can lead to changes in policy and procedure resulting in more fluid communication between the public and the government that serves them. America needs hope right now, and Americans need to be more involved in their government. ### CONTACT: CONTACT: Joanne COMPANY: ThinkCareBelieve EMAIL: joanne@ WEB: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Oscar Health (OSCR) Soars 13% on Fourth Straight Day, Here's Why
Oscar Health, Inc. (NYSE:OSCR) is one of the Oscar Health extended its winning streak to a fourth consecutive day on Friday, jumping 13.05 percent to close at $21.22 apiece as investor sentiment was influenced by the previous days' surge. During the shortened, four-day trading week, shares of Oscar Health, Inc. (NYSE:OSCR) already grew by 52 percent, with analysts pointing to meme trading as having buoyed its share prices. Additionally, investor sentiment was supported by a new proposal for Medicare that would allow individuals and employers to enroll in a new version called 'Part E.' A close up of a patient and a healthcare professional engaging in conversation, showing the company's commitment to patient care. While this would heighten competition with private insurers such as Oscar Health, Inc. (NYSE:OSCR), the voluntary enrollment could potentially delay or prevent Medicare's sooner-than-expected insolvency. While we acknowledge the potential of OSCR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
